Results 1 to 10 of about 271,261 (306)
Qualitative and quantitative evaluation of computed tomography changes in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: a retrospective observational study
Frontiers in Pharmacology, 2023 Introduction: The availability of highly effective triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator combination therapy with elexacaftor–tezacaftor–ivacaftor (ETI) has improved pulmonary outcomes and quality of life of people ...Sabine Dettmer, Sabine Dettmer, Oliver Weinheimer, Oliver Weinheimer, Annette Sauer-Heilborn, Oliver Lammers, Mark O. Wielpütz, Mark O. Wielpütz, Jan Fuge, Jan Fuge, Tobias Welte, Tobias Welte, Frank Wacker, Frank Wacker, Felix C. Ringshausen, Felix C. Ringshausen, Felix C. Ringshausen +16 moredoaj +1 more sourceInterleukin‐17A and interleukin‐22 production by conventional and non‐conventional lymphocytes in three different end‐stage lung diseases
Clinical & Translational Immunology, 2022 Objectives The contribution of adaptive vs. innate lymphocytes to IL‐17A and IL‐22 secretion at the end stage of chronic lung diseases remains largely unexplored. In order to uncover tissue‐ and disease‐specific secretion patterns, we compared production Melanie Albrecht, Olga Halle, Svenja Gaedcke, Sophia T Pallenberg, Julia Camargo Neumann, Marius Witt, Johanna Roediger, Marina Schumacher, Adan Chari Jirmo, Gregor Warnecke, Danny Jonigk, Peter Braubach, David DeLuca, Gesine Hansen, Anna‐Maria Dittrich +14 moredoaj +1 more sourceCiliary Ultrastructure Assessed by Transmission Electron Microscopy in Adults with Bronchiectasis and Suspected Primary Ciliary Dyskinesia but Inconclusive Genotype
Cells, 2023 Whole-exome sequencing has expedited the diagnostic work-up of primary ciliary dyskinesia (PCD), when used in addition to clinical phenotype and nasal nitric oxide. However, it reveals variants of uncertain significance (VUS) in established PCD genes or (Ben O. Staar, Jan Hegermann, Bernd Auber, Raphael Ewen, Sandra von Hardenberg, Ruth Olmer, Isabell Pink, Jessica Rademacher, Martin Wetzke, Felix C. Ringshausen +9 moredoaj +1 more sourceInhalation therapy in the next decade : Determinants of adherence to treatment in asthma and COPD [PDF]
, 2018 Peer reviewedPublisher ...Amaducci, Sandro, Bacci, Elena, Baldacci, Sandra, Bartoli, Maria L., Beghi, Gianfranco M., Benfante, Alida, Brighindi, Sara, Casali, Lucio, Castiglia, Daniela, Cazzola, Mario, Celi, Alessandro, Cianchetti, Silvana, Colombo, Giorgio, Crimi, Claudia, d'Alcontres, Martina Stagno, Dente, Federico L., Di Maria, Annalisa, Di Maria, Giuseppe, Donner, Claudio F., Hui Xin, Shaylynn Yu, Latorre, Manuela, Lavorini, Federico, Maio, Sara, Mannini, Claudia, Messina, Riccardo, Paggiaro, Pier Luigi, Pignatti, Patrizia, Pistolesi, Massimo, Price, David, Scichilone, Nicola, Simoni, Marzia, Spanevello, Antonio, Tan, Shwana, Torchio, Roberto, Viegi, Giovanni, Visca, Dina, Wouters, Emiel F.M. +36 morecore +17 more sourcesMuco-Obstructive Lung Diseases
New England Journal of Medicine, 2019 A spectrum of lung diseases that affect the airways, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, primary ciliary dyskinesia, and non–cystic fibrosis bronchiectasis, can be characterized as muco-obstructive diseases. These diseases have the clinical features of cough, sputum production, and episodic exacerbations that are ...Boyton, RJ, Altmann, DMopenaire +8 more sourcesDiet and Obstructive Lung Diseases [PDF]
Epidemiologic Reviews, 2001 The results presented in this review suggest that the impact of nutrition on obstructive lung disease is most evident for antioxidant vitamins, particularly vitamin C and, to a lesser extent, vitamin E. By decreasing oxidant insults to the lung, antioxidants could modulate the development of chronic lung diseases and lung function decrement ...I, Romieu, C, Trengaopenaire +2 more sourcesSpirometric and anthropometric improvements in response to elexacaftor/tezacaftor/ivacaftor depending on age and lung disease severity
Frontiers in Pharmacology, 2023 Introduction: Triple-combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy with elexacaftor/tezacaftor/ivacaftor (ETI) was introduced in August 2020 in Germany for people with CF (pwCF) ≥12 years (yrs.) of age and in ...Katharina Schütz, Katharina Schütz, Sophia Theres Pallenberg, Sophia Theres Pallenberg, Julia Kontsendorn, David DeLuca, David DeLuca, Cinja Sukdolak, Cinja Sukdolak, Rebecca Minso, Rebecca Minso, Tina Büttner, Tina Büttner, Tina Büttner, Martin Wetzke, Christian Dopfer, Annette Sauer-Heilborn, Felix C. Ringshausen, Felix C. Ringshausen, Felix C. Ringshausen, Sibylle Junge, Burkhard Tümmler, Burkhard Tümmler, Gesine Hansen, Gesine Hansen, Anna-Maria Dittrich, Anna-Maria Dittrich +26 moredoaj +1 more sourceThe Impact of HAART on the Respiratory Complications of HIV Infection: Longitudinal Trends in the MACS and WIHS Cohorts [PDF]
, 2013 Objective: To review the incidence of respiratory conditions and their effect on mortality in HIV-infected and uninfected individuals prior to and during the era of highly active antiretroviral therapy (HAART).A Johannessen, A Lindberg, AK Chaturvedi, Alison Morris, AN Phillips, B Balbi, BR Celli, Charles R. Rinaldo, Christine B. Alden, DB Coultas, E Gouws, EA Engels, EC Seaberg, Eric C. Kleerup, Eric C. Seaberg, F Gutin, FJ Palella Jr, FN Engsig, G. K. Balasubramani, GA D’Jaen, GD Kirk, GM Allardice, GM Clifford, J Almirall, Jason F. Okulicz, JE Kaplan, JF Murray, JM Wallace, John Phair, Joseph B. Margolick, JR Grubb, K Crothers, K Crothers, K Crothers, K Sigel, L Dal Maso, Laurence Huang, Lawrence Kingsley, M Bower, M Frisch, M Herida, Matthew R. Gingo, MR Gingo, MR Gingo, MS Shiels, NA Hessol, Nancy A. Hessol, O Sitbon, PY Hsue, R McKenzie, RA Kaslow, RD Moore, RE Hirschtick, RM Phelps, Roger Detels, Ruth M. Greenblatt, S Hariri, Sarah H. Sutton, SB Foster, SE Barkan, Stephen R. Wisniewski, Susan Holman, T Takahashi, V Dufour +63 morecore +14 more sourcesPolymerization of misfolded Z alpha-1 antitrypsin protein lowers CX3CR1 expression in human PBMCs
eLife, 2021 Expression levels of CX3CR1 (C-X3-C motif chemokine receptor 1) on immune cells have significant importance in maintaining tissue homeostasis under physiological and pathological conditions.Srinu Tumpara, Matthias Ballmaier, Sabine Wrenger, Mandy König, Matthias Lehmann, Ralf Lichtinghagen, Beatriz Martinez-Delgado, Elena Korenbaum, David DeLuca, Nils Jedicke, Tobias Welte, Malin Fromme, Pavel Strnad, Jan Stolk, Sabina Janciauskiene +14 moredoaj +1 more source